Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The closing price of Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) was $2.4 for the day, down -2.04% from the previous closing price of $2.45. In other words, the price has decreased by -$2.04 from its previous closing price. On the day, 0.86 million shares were traded. MRVI stock price reached its highest trading level at $2.45 during the session, while it also had its lowest trading level at $2.345.
Ratios:
Our analysis of MRVI’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 4.49 and its Current Ratio is at 5.16. In the meantime, Its Debt-to-Equity ratio is 1.40 whereas as Long-Term Debt/Eq ratio is at 1.34.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Robert W. Baird on February 26, 2025, Downgraded its rating to Neutral and sets its target price to $3 from $9 previously.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 31 ’25 when ORESHACK KURT sold 25,000 shares for $5.03 per share. The transaction valued at 125,750 led to the insider holds 167,618 shares of the business.
ORESHACK KURT bought 25,000 shares of MRVI for $125,750 on Jan 31 ’25. On Nov 12 ’24, another insider, DeFord John A, who serves as the Director of the company, bought 17,500 shares for $5.75 each. As a result, the insider paid 100,625 and bolstered with 70,046 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MRVI now has a Market Capitalization of 878510464 and an Enterprise Value of 650522624. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.61 while its Price-to-Book (P/B) ratio in mrq is 1.31. Its current Enterprise Value per Revenue stands at 2.959 whereas that against EBITDA is -10.805.
Stock Price History:
The Beta on a monthly basis for MRVI is 0.29, which has changed by -0.7342193 over the last 52 weeks, in comparison to a change of 0.14460516 over the same period for the S&P500. Over the past 52 weeks, MRVI has reached a high of $9.60, while it has fallen to a 52-week low of $1.66. The 50-Day Moving Average of the stock is -1.64%, while the 200-Day Moving Average is calculated to be -29.69%.
Shares Statistics:
MRVI traded an average of 1.69M shares per day over the past three months and 1411250 shares per day over the past ten days. A total of 144.62M shares are outstanding, with a floating share count of 103.37M. Insiders hold about 28.55% of the company’s shares, while institutions hold 77.17% stake in the company. Shares short for MRVI as of 1753920000 were 13310622 with a Short Ratio of 7.86, compared to 1751241600 on 13753559. Therefore, it implies a Short% of Shares Outstanding of 13310622 and a Short% of Float of 10.99.
Earnings Estimates
A comprehensive evaluation of Maravai LifeSciences Holdings Inc (MRVI) is underway, with the input of 11.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.07, with high estimates of -$0.03 and low estimates of -$0.11.
Analysts are recommending an EPS of between -$0.23 and -$0.38 for the fiscal current year, implying an average EPS of -$0.3. EPS for the following year is -$0.2, with 12.0 analysts recommending between -$0.07 and -$0.47.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 12 analysts. It ranges from a high estimate of $53.9M to a low estimate of $45.45M. As of the current estimate, Maravai LifeSciences Holdings Inc’s year-ago sales were $65.2MFor the next quarter, 12 analysts are estimating revenue of $48.54M. There is a high estimate of $55.8M for the next quarter, whereas the lowest estimate is $44.02M.
A total of 13 analysts have provided revenue estimates for MRVI’s current fiscal year. The highest revenue estimate was $203.5M, while the lowest revenue estimate was $185.4M, resulting in an average revenue estimate of $191.82M. In the same quarter a year ago, actual revenue was $259.19MBased on 12 analysts’ estimates, the company’s revenue will be $205.37M in the next fiscal year. The high estimate is $223.33M and the low estimate is $192M.
